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ABSTRACT
Retinitis Pigmentosa (RP) is a group of hereditary genetic disorders, all causing
degradation of the retina through loss of rod photoreceptor cells, ultimately causing loss
of vision and in many cases complete blindness. Despite the prevalence of Retinitis
Pigmentosa disorders, safe and effective treatment methods have not yet been approved
to stop or regain vision loss in patients diagnosed with RP. However, the ophthalmic field
as a whole is working on several new technologies and procedures in order to both slow
loss of vision as well as potentially regain lost sight. In this thesis, I describe the genetic
causes and effects of retinitis pigmentosa, followed by an analysis of current
experimental treatments. Possible treatments were screened based on the following
criteria; potential release date, adverse effects, ability to treat children, convenience, and
the exclusion of patients for each therapy. Finally, I lend to support my claim that stem
cell therapy by mesenchymal stem cells through intravenous infusion appears to be the
most effective and safest method of experimental treatments available today.
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CHAPTER 1

INTRODUCTION

Retinitis Pigmentosa

Retinitis Pigmentosa or RP refers to a group of inherited conditions all resulting
in a gradual progressive reduction of vision through the loss of light-sensing cells of the
retina (Zhang, 2016). Disorders of the eye, related to RP can be caused by variations in
any of 60 genes that affect the retina, these variations lead to the eventual death of
photoreceptor cells and pigmentation abnormalities. The differences in the degree of
vision loss experienced by an individual correlates to the number of retinal cell deaths,
with complete blindness being uncommon (Daiger, 2007). Retinitis pigmentosa disorders
are hereditary. The gene affected often influences the speed of photoreceptor cell loss,
level of progression, and displayed symptoms (Zhang, 2016). However, the typical
progression regardless of other factors is as follows; loss of night vision (night blindness),
blind spots in peripheral vision, loss of peripheral vision, and effects to central vision
which often impairs tasks such as reading, driving, and recognizing faces (Birtel et al.,
2021). Some patients can retain cone photoreceptor cells if disease progression is slow
enough as to not induce catastrophic damage to the rest of the eye, additional some
patients' photoreceptor loss is slow enough that they will not reach blindness before end
of life.

1

Structures Affected
The disease primarily affects three related components of the eye; the general
retina, photoreceptor cells, and the retinal pigment epithelium (RPE). The retina is
located at the back of the eye and is responsible for the detection of both light intensity
and color. It is constructed of millions of light-sensitive cells called photoreceptors. Once
fully developed, the photoreceptor cells cannot regenerate if damaged, leading to a
progressive loss of function in each affected photoreceptor. With the substantial loss of
photoreceptor cells the retina becomes unable to function properly leading to an inability
to process and transmit sight information to the brain (Zhang, 2016). There are two types
of photoreceptor cells: rods, which allow for light signaling, and cones which are
responsible for fine detail and color, together they perform phototransduction which
converts light to signals that can stimulate biological processes (Molday & Moritz, 2015).
These structures are supported by the pigment epithelium, a pigmented layer of cells next
to the retina which serves as a barrier between photoreceptors and a layer of blood
vessels. The role of the RPE is to nourish the nerve tissue of the retina and maintain its
health (Klimanskaya, 2006). When photoreceptors die, imbalances within the eye begin
to occur, including oxidative damage. This oxidative damage can harm the pigment
epithelium and cause significant risk for photoreceptor cell death due to lack of
nourishment.
Phototransduction
The above structures are critical to an early stage of vision that contributes to our
visual processing system termed phototransduction. In this process, photoreceptor cells
serve as intermediate messengers assisting in the process of sending signals of light
2

perception to the brain. This is accomplished as photoreceptor cells are stimulated by the
intensity of light. After light is absorbed by a photoreceptor its cell membrane
hyperpolarizes thereby reducing the rate of transmitter release. In dark conditions, the
photoreceptors are depolarized, and the rate of transmitter release is high. Change in
polarization is facilitated in the cell by ion channels permeable to Na+ and Ca++ in the
outer segment of the membrane. As light is introduced, the channels close, allowing
hyperpolarization to occur, thus reducing transmitter release to the photoreceptor
synapse. cGMP levels regulate the opening and closing of the channels. In darkness,
cGMP levels are high, keeping channels open whereas when exposed to light, levels
drop, and channels begin to close. Photons create the cascade that reduces cGMP levels
mediating the rate of the photo transmitter release. The photon will first be absorbed by a
photopigment, rhodopsin, containing a light-absorbing chromophore, in the receptor disk
of the cell. After absorbing the photon, a conformational change will occur triggering a
series of alterations in the protein component of the molecule. The alteration activates the
intercellular messenger transducin. Transducin then activates a phosphodiesterase that
hydrolyzes cGMP lowering its concentration therefore reducing its binding ability to the
channels, which keep them open (Stryer, 1983). The transmitters previously mentioned
signal the numbers of photons absorbed thereby communicating the quality and quantity
of light by graded membrane polarization to bipolar cells also housed in the retina,
bipolar cells can then communicate with the ganglion and amacrine cells of the brain (Li
et al., 2012). When photoreceptors are damaged or lost due to retinitis pigmentosa
conditions, this photoreceptor-bipolar-ganglion cellular pathway is first dampened and
then destroyed. After cells have become dormant or begun apoptosis, they can no longer
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serve phototransduction functions. RP-related diseases often attack the rod cells first
which lie on the periphery of the eye, leading to loss of peripheral vision and producing
tunnel vision in early stage patients. Since both rod and cone cells complete
phototransduction, a patient can still have some vision even after all rod cells are lost.
However, complications of rod cell death often trigger the death of cone cells as well,
leaving no remaining cells with the ability to photo-transduce signals.
Hereditary Development
Retinitis Pigmentosa, because of its serious hereditary influences on retinal
development, greatly complicates any possible treatments. First, the disease can arise
from a number of genes, many of which have not yet been identified, leading to
complications in the diagnostic process and application of appropriate treatments.
Additionally, retinitis pigmentosa can arise through several modes of inheritance making
diagnoses increasingly difficult, as well as result from several different mutations on the
same gene which add to the incredibly large number of variations the disease may take
on. Each gene associated with the disorder is directly linked to photoreceptor cells,
affecting structure and or function of the cell in some capacity. When mutations arise
within these genes a gradual loss of photoreceptor cells in the retina begins, therefore
characterizing the disorder (Fahim et al., 1993).
The current modes of inheritance causing disorders connected to RP include;
autosomal dominant which can result from a single inherited dominant mutated allele,
autosomal recessive or requiring a mutated allele from both parents, X-linked which stem
from mutation on an expressed X chromosome, or mitochondrial occurring through
maternal mitochondrial DNA. Mutations can also arise with no previous family history
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indicated which are categorized as isolate (Phelan, Mol Vis 2000; 6:116-124., n.d.). This
heterogeneity makes not only determining which gene is affected incredibly difficult, but
also genetic counseling and approaches for gene therapy.
Research on this topic has exponentially increased in recent years with several
dozen teams across the world attempting to identify the genetic roots of RP. However,
only 56 of the estimated 70 or more genes which may cause these disorders have been
identified, making it possible to detect the specific mutations in only 30-80% of cases
(Phelan, Mol Vis 2000; 6:116-124., n.d.) (Daiger et al., 2013). Utilization of deep
sequencing or next-generation sequencing (NSG) has aided researchers in the discovery
of new genes causing RP. As well, several of the diseases overlap with one another and
single gene mutations have been found to cause multiple diseases, this is exemplified by
the fact that some identical mutations have been found to manifest and produce different
clinical findings. The heterogeneous nature of RP causes greater confusion as RP can
arise from over 3,100 mutations across more than 50 genes. RP is defined as genetically,
allelically, phenotypically, and clinically heterogeneous, this creates substantial
confusion for clinicians and researchers desperately attempting to diagnose and create
new treatment approaches (Daiger et al., 2013).
Genes Discussed in Experimental Treatments
PDE6A and PDE6B Mutations.
Both PDE6A and PDE6B are catalytic subunits of phosphodiesterase 6 (PDE6), a
holoenzyme located in the integral membranes of retinal photoreceptors, responsible for
the reduction of cytoplasmic levels of cyclic guanosine monophosphate (cGMP). While
mutation in both subunits have been seen, the individual properties of PDE6A and
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PDE6B are unknown and therefore they are often discussed in tandem (Muradov et al.,
2010). When this enzyme is lost due to mutation of the gene producing PDE6A or its
subunits, persistent and chronic elevated cGMP levels can occur (STZ eyetrial, 2020). As
a result of elevated cGMP increased calcium concentrations begin to flow into the cell
causing the hyperactivation of cell death pathways, therefore contributing to the death of
photoreceptor cells. Additionally, due to cGMP’s role in phototransduction, high levels
can lead to problems in the process of visual signal transmission and amplification when
incorrect concentrations are present therefore disrupting the phototransduction process
and ability to convert light signals into sight (PDE6A Phosphodiesterase 6A [Homo
Sapiens (Human)] - Gene - NCBI, n.d.).
Rd1 Mice. The Rd1 mouse was created in order to model autosomal recessive RP
patients, so researchers could utilize them in retinitis pigmentosa experimental testing. In
order mimic this form of RP, the mice are genetically modified for a mutation that affects
the “expression of the β subunit of phosphodiesterase 6 (PDE6) leading to accumulation
of cGMP that is thought to trigger rod photoreceptor degeneration (Kalloniatis et al.,
2016).” These mice are used in several methods of experimental testing including those
that target the specific mutation and others such as antioxidant treatments and stem cell
therapies which attempt to combat the harmful cascade created in the eye when
photoreceptors begin to die.
PRGR Gene Mutation
RPGR gene mutations account for about 10 -15% of RP cases and approximately
70% of X-linked RP cases. Despite its prominence, the mechanism which results in
photoreceptor cell dysfunction due to modified RPGR genes is unknown (Zhang et al.,
6

2019). It is currently known that the gene functions to provide instruction for protein
creation necessary for normal vision, however, the protein products function is still
unknown. Studies suggest that the protein created is integral to cilia function, which
assists in the perception of vision. One protein segment created by RPGR is as the
ORF15 exon, this exon or protein, is expressed solely in the retina and within
photoreceptor cells. It has been suggested that the protein product may regulate the
function of cilia which are thought to play a role in maintaining photoreceptors (RPGR
Gene, n.d.).
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CHAPTER 2

RETINITIS PIGMENTOSA TREATMENTS

Current Treatment

Unfortunately, due to the heterogeneity listed above, learning about both RP and
its effective forms of treatment has been extremely difficult. Currently treatment for those
who are diagnosed are based on palliative care and helping those with the disease to
maintain the best standard of living possible with loss of vision and blindness. No FDA
approved treatments have been found to stop disease progression or return lost vision.
Until a cure is found clinicians will continue to administer standard palliative treatments
recommended by the National Eye Institute including; receiving care from occupational
therapists, orientation and mobility specialists, and certified low vision therapists.
Patients are also evaluated and administered low vision aids such as special lenses,
computer text programs, closed circuit television, and portable lighting. Vitamin A
treatments and the implementation of Argus II, an electrode which helps relay
information to the brain, have been used in late stage retinitis pigmentosa patients in
which the electrodes probable benefits outweigh potential harm from the device (Retinitis
Pigmentosa | National Eye Institute, n.d.).
Experimental Treatments
Just as the disorder is complex and diverse, the experimental treatments being
explored are as well. Treatments currently being studied range widely and aim for
solutions including, preventing disease progression, restoring partial vision, and complete
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restoration of vision. Currently, Vitamin A supplements and Argus II implementation are
becoming more widely used methods of treatment. However, these treatments are unable
to stop the disease progression or restore lost vision. The procedures discussed in this
section are working towards vision and photoreceptor restoration. With further
exploration, scientific advances could begin to restore lost sight in retinitis pigmentosa
patients.
The following treatments were selected for based on both the most recent
experimentation while taking into consideration mutation and method diversity. The
following studies range in treatment for most retinitis pigmentosa patients to highly
targeted methods such as those focused on the Pdea6 gene and X-linked cases. Each
study also utilizes a different form of potential intervention including antioxidants,
optogenetics mediated gene therapy, subretinal injection, sub-tenon injection and
intravenous infusion. While only three of these potential treatment methods focus on
human studies, due to lack of trials which have reached this phase of testing, animal
models such as the Rd1 mice, college surgeon rats, and mutated dogs can serve
researchers in gaining valuable insights and data on how these treatments may affect the
human eye with similar mutations.
Antioxidant Treatments
Oxidative Stress and Retinitis Pigmentosa. As previously discussed, Retinitis
Pigmentosa is a genetic disorder, which can be induced by a number of differing gene
mutations leading to the loss of photoreceptor cells in the eye. Due to the clinical
symptoms, it has been deduced that the rod photoreceptors which account for 95% of all
photoreceptors are typically first to become affected, producing the tunnel-like vision
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symptoms while the central vision cones are maintained. However, over time complete
blindness can occur which is thought to be the result of oxidative stress related to
photoreceptor cell loss. A catastrophic cascade is induced when rod cell death begins,
rods are responsible for metabolizing excess oxygen and as they are reduced a buildup of
oxygen occurs with fewer cells capable of metabolizing it, therefore this loss of cells
causes toxic oxidative stress to the entire system. This cascade was summarized as “a
cascade of molecular phenomena—such as para-inflammation, synaptic impairment,
apoptosis, and cell death—which hugely impact visual function, is triggered (Limoli et
al., 2020).” As more rod cells continue to die from both the disease and now present
oxidative stress even more excess oxygen is accumulated which eventually begins to
cause cone cell apoptosis and total vision loss. While the body does have mechanisms in
place to alleviate oxidative stress, the rapid loss of cells creates an insurmountable
environment imbalance, often the retinal pigment epithelium is also damaged by the rod
loss and subsequent oxidative damage. Transduction pathways and gene expression are
also affected by oxidative stress damaging all cellular components including
phospholipid membranes, proteins, and nuclear and mitochondrial DNA causing even
more damage to the photoreceptors and RPE (Komeima et al., 2007). At this point retinal
autophagy to catabolize the oxidatively damaged proteins and organelles may occur, but
this can cause a buildup of autophagosomes, which deliver engulfed substrates into
lysosomes for degradation. This leads to continued and increasing stress which only
harms cells further, leading to apoptosis of all cells within the system, including the
cones.
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Antioxidant Treatments in Mouse Models of Retinitis Pigmentosa.
Antioxidant treatments are attractive as they may not require gene specific
approaches to help delay the loss of photoreceptors. However, these treatments must
begin before any significant loss of photoreceptors to be effective. This treatment could
substantially decrease the amount of oxidative pressure on the eye therefore increasing
the chances of survival of the remaining rods and cones. In the following study conducted
by John Hopkins School of Medicine, antioxidant “cocktails'' were administered to
several different testing mice to see the effects on different variants of hereditary retinitis
pigmentosa (Komeima et al., 2007).
Prior to the above study, the slowing of RP through the use of antioxidant
“cocktails” had been achieved in Rd1 mice. These mice are genetically mutated to model
rapidly progressive recessive RP. The Rd1 mice treated with antioxidant cocktails
produced results which indicated a slowing of the progression of rod cell death and
reduction in oxidative damage. Therefore, the treatment created a better environment for
the maintenance of cone cells (Sanz et al., 2007). The Hopkins study explored if similar
methods could be effective for other models of RP, therefore, they used both Rd10/Rd10
and Q344ter mice. Rd10/Rd10 mice house a mutation on the same gene as Rd1 mice,
however they provide a model for more slowly progressive RP, while Q344ter mice carry
the mutation of many patients with rapidly progressive dominant RP. While results varied
between the mice, both showed positive results. The Rd10/Rd10 mice exhibited a
slowing of both cone and rod cell death as well as preservation of photoreceptor function.
In the Q344ter mice, there was not significant slowing of rod death, likely due to the
dominant mutation which produced toxic gene products fatal to rods, however, cone
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density was significantly greater in antioxidant treated mice. This finding suggests that
cone death is a result of oxidative damage as well as that it can be mediated with the
correct combination of antioxidants (Komeima et al., 2007).
Vitamin A Palmitate Antioxidant in Human Trials. Vitamin A Palmitate trials are
currently being conducted in order to see if its antioxidant properties can produce slowing
of rod photoreceptor deaths and survival of cone cells by diminishing oxidative stress.
These trials are currently being conducted in humans and have produced a wide variety of
results, with differing validity values concerning if rod cell death is being slowed.
Clinical researchers appear to have differing opinions on the vitamins ability to slow the
effects of RP including retinal loss of function in adults (Berson et al., 2018). No
conclusive evidence has been found on its ability to slow rod cell degradation or protect
cones from oxidative stress. Studies in children also show no conclusive results
(Schwartz et al., 2020).

(Figure 1. Structure of Vitamin A Palmitate)

12

Gene Therapy
Optogenetics- Mediated Gene Therapy. Unlike potential antioxidant therapies
optogenetic – mediated gene therapy is highly targeted, however, if successful it could
bring treatment to a large division of RP patients. This therapeutic approach is currently
being investigated in the same Rd1 mice used in antioxidant studies who have a
“mutation of rod cGMP- specific 3′,5′-cyclic phosphodiesterase subunit beta (PDE6B)
gene related to the hydrolysis of cGMP”, a mutation similar to many human patients
suffering from autosomal recessive RP (Tomita & Sugano, 2021).
One form of gene therapy is transducing ChR2 or Chlamydomonas- derived
channel rhodopsin -2, into differing order neurons. Several studies were summarized each
producing greater light stimulation after gene-mediation. When the retinal ganglion cells
were targeted in Rd1 mice, visual responses were restored. The same phenomenon
occurred when Royal College Surgeons rats, which have similar mutations to Rd1 mice,
were treated with an adeno-associated virus- mediated ChR2 gene transferred into
ganglion cells. Additionally, reports of restoration of vision have been found in Rd1 mice
in which the gene was transduced into the second order neurons, or bipolar cells, which is
thought to contribute to the restoration of connection in the phototransduction pathway.
While still in preliminary phases, researchers hope to transduce the gene into third-order
ganglion neurons, which would restore visual functioning of any surviving retinal
neurons. Clinical trials have begun using ChR2 in RP patients in the United States.
Despite the considerable promise of ChR2 – gene therapy, multiple limitations of
the therapy were cited. These included low light and wavelength sensitivity which
necessitated intense light in order to activate the cells and the high intensity light needed
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to activate the cells toxic effect on native photoreceptor cells. Additionally, most objects
reflecting wavelengths below 550nm appeared blue to the small animal treatment
subjects. Due to these limitations, another gene therapy is being studied using mVchR1
or Volvox- derived ChR1, which has a broader, red- shifted action spectrum potentially
allowing RP patients to see a broader range of colored objects. In this form of genemediated therapy, blind rats were treated with AVV vectors and stimulus was recorded at
468nm of LED, therefore indicating a broader range of color could be seen with this
treatment (Tomita & Sugano, 2021).
AAV- Pde6a Gene Therapy in Large Animals. Researchers at the University of
Florida College of Medicine were also interested in AVV vectors, however, they decided
to isolate the PDE6A gene in order to produce positive results of photoreceptor survival.
Mutations in the alpha or beta subunits of the rod phosphodiesterase (PDE6) result in
autosomal recessive RP, and each of these mutations respectively account for
approximately 4% of patient cases or 8% together. Ten PDE6A mutant dogs were studied
and received subretinal injections using Pde6a delivery by capsid – mutant adenoassociated virus serotype 8 (Mowat et al., 2017). Prior attempts with AVV serotype 5
gene augmentation therapy were unsuccessful, however they prompted the researchers to
develop this therapy. It was hypothesized that delivery of the treatment needed to be
conducted as the eye was still developing and the use of highly efficient, rapid- onset,
viral vectors was necessary (Mowat et al., 2017). Thus, the dogs were injected at a mean
of 36 days of age, while their eyes had not yet fully developed, with one eye injected with
AAV-Pde6a and the other eye left alone for control.
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The dogs were monitored over four months with several forms of retinal testing
for thickness and light responses, as well as participating in tunnel mazes with both their
injected and uninjected eyes separately. After testing was completed, the dogs were
euthanized, and their retinas preserved for further testing unable to be done on a living
eye. The study produced positive results in almost every testing field, however, some
adverse effects were observed in the treated areas. The results included improvement to
dim light vision as measured by electroretinographic testing, preserved photoreceptor
layer thickness, evidence of rod function, improved survival of both rods and cones, and
return of appropriate rhodopsin localization. Unfortunately, persistent regions of retinal
separation and rosette formation occurred in both the AAV-Pde6a and control vector
injected regions, suggesting a flaw in administration method rather than the injected gene
(Mowat et al., 2017).
Initial X-linked Gene Therapy Results in Humans. Clinical trials have begun
using similar methods to those in the previous study, initial findings support that with the
use of sub-retinal injected adeno-associated viral vector encoding codon optimized
human RPGR (AAV8-coRPGR) gains in visual functioning can occur. However, the
requirements for eligibility in this treatment are incredibly specific and only proved
positive results for six out of eighteen male participants, all suffering from a form of Xlinked retinitis pigmentosa resulting from RPGR gene mutation. While the results of this
study were varied and six patients had increased visual performance, it was determined
through this study the “mid-dose” range of the vector was most successful without
causing negative effects related to inflammation (Cehajic-Kapetanovic et al., 2020).
Stem Cell Therapy
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Management of Retinitis Pigmentosa by Wharton’s Jelly derived Mesenchymal
Stem Cells (MSC’). One of the most promising methods of photoreceptor preservation
thus far has been the use of mesenchymal stem cell injection into the sub-tenon space
which revives dormant cells and can halt the effects of retinitis pigmentosa symptoms
within the retina. In this study, 32 patients in differing stages of retinal decline and
suffering from different forms of retinitis pigmentosa, received injections of MSC’s. The
stem cells were acquired from a single umbilical cord given with the mother’s consent
and injected into the sub-tenon space of the eye. Only one eye was tested per individual
and results were compared between the injected and non-injected eyes. These patients
were followed for 6-months receiving an extensive panel of ophthalmic testing at one
month intervals. Once injected, the MSC’s are assumed to work as an anti-inflammatory
agent, help nourish and maintain the retinal pigment epithelium and reactive dormant rod
photoreceptor cells. Significant improvements to rate of photoreceptor loss or
maintenance of progression were seen in a majority of injected patients. The
photoreceptors of multiple patients regained thickness in the inner rings, 1 through 3, and
showed improvement in visual functioning, however, the outer fourth and fifth rings
showed little to no improvement throughout the testing pool. However, it is known that
most forms of RP develop from the outer periphery vision inward so it is likely these
cells had already undergone apoptosis. (Emin &uuml et al., 2020).
Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells. Similar to the
prior study, another team of researchers conducted trials with MSC’s, however, instead of
performing surgery or injection into the sub-tenon space, the cells were introduced into
patients through the form of intravenous infusion. This study was composed of 32
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individuals, all suffering from late stage clinical RP. Results were similar to those when
the treatment was injected, however, the cells effectiveness was for a slightly shorter
duration. In this study, 96.9% of patients improved or maintained vision 1 month after
infusion. Some patients experienced vision losses, however vision loss is to be expected
in individuals with RP, and likely did not indicate negative effects, rather no positive
results. The positive effects for most diminished after three – months post infusion when
most stopped experiencing visual gains. However, 81.3% patients maintained the results
of improved vision throughout the twelve month trial period. With no serious adverse
effects in any patients, this study indicated the safety of intravenous MSC injection, as
well as the potential positive effects for patients suffering with multiple forms of retinitis
pigmentosa (Zhao et al., 2020).
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CHAPTER 3

RETINITIS PIGMENTOSA TREATMENT DISCUSSION

Current Stages of Experimental Treatments

This section covers the current state of treatments concerning Retinitis
Pigmentosa followed by my suggestion of a future treatment. While some treatment
options may be better than others, each treatment discussed below holds the potential to
help those struggling with Retinitis Pigmentosa. Generally, those first approved from
clinical trial will likely be used until better treatment methods are found. However, some
are far closer than others to clinical release. One antioxidant treatment, Vitamin A
palmitate, is currently in use as a treatment option for patients suffering from most forms
of retinitis pigmentosa but unfortunately, after years of study, no conclusive or significant
positive effects have been indicated. Currently there are no antioxidant cocktails in
clinical study. Therefore, of the treatments discussed we are least likely to see them used
in the near future. In order to do so researchers will first need to solve problems such as
which antioxidants to include, amounts of each, and best method of administration.
Gene therapy for retinitis pigmentosa, conversely, has recently entered very early
clinical trial stages in specific retinitis pigmentosa patients. As earlier discussed, some
patients housing X-linked PRGR mutations showed positive results when treated with
AAV8-coRPGR gene therapy. Mice, rats, and dogs with PDE6A and PDE6B mutations
have shown gains in visual functioning through optogenetic mediated and AVV- Vector
gene therapy. While it is difficult to assess a timeline of trials still focused on small and
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large animal species, the initial trials in x-linked RPGR patients showed that through subretinal injection the gene therapy could delay photoreceptor death. Also, with the
additional information from the trials indicating the optimal dosage of this treatment it is
likely to see great gains in the near future, but is still not yet effective for treating this
specific disorder.
Of the all the treatments discussed, stem cell therapy appears to be the closest to
clinical approval. In both forms of clinical treatment, subretinal injection of MSC’s and
intravenous infusion of MSC’s, significant positive results indicating the slowing of
photoreceptor cell death and even the revival of dormant cells were seen with very few if
any adverse side effects. Based on their relative success and lack of serious adverse
effects we will likely see these forms of treatment approved soon.
Adverse Effects of Treatments
It is also important to consider the adverse effects of each treatment. It is difficult
to discuss those of the antioxidant treatment as the cocktails were studied in mice, and we
do not yet know how they will react with the human body. Additionally, while Vitamin A
palmitate is not known to have any serious adverse effects, it has also not been proved to
be an effective form of treatment. However, other forms of experimental treatment have
caused serious side effects which could lead to the loss of vision in some cases, most
occurring in gene therapy treatment approaches. Within the study utilizing PDE6A dog’s
serious complication from injection occurred including retinal separation and rosette
formation. The human X-linked trials also had adverse effects, although less serious,
reporting blebs, or fluid filled blisters on the surface of the eye, at the injection site. Post
injection irritation and inflammation also occurred in a few of the cases. While these
19

forms of therapy could ultimately restore vision, the risks seem to be greater with the
method of administration currently used. However, injection into the sub-tenon space, as
completed by the Wharton’s jelly derived stem cell trial, could decrease the number of
adverse effects seen as the patients in these trials did not experience any severe adverse
effects, nor did those administered intravenous MSC’s.
Unknown Long Term Effects of All Treatments. It is also important to note that
researchers are unsure of the long term effects of all stated experimental trials. Once
again, antioxidants are difficult to discuss as these treatment approaches have not yet
been tested in humans, but there could be complications due to a buildup of introduced
vitamins and foreign materials.
In regard to stem cell therapy treatment, these therapies could cause the
development of severe long term side effects as it would currently require regular
treatments. It has been stated in both studies that the effects of the initial injection will
not remain for extended periods of time, requiring multiple procedures in order to
maintain vision. Both methods cited few adverse side effects, however, with repeated and
continued use this may not be the case. With subretinal injection evidence indicated
benefits were highest up to six months and intravenous up to three. Both papers discussed
issues that could arise from the rapid nature of proliferation in stem cells. If these cells
were to migrate to undesired areas and build up in inappropriate locations, this could
cause a slew of issues for other systems. Also, with additional therapies injection sites
become more at risk for complications while sub- tenon injection seems to be a highly
beneficial method without the issues of sub-retinal injections experienced, it is unknown
the damage repeated exposure could cause.
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Similarly, to stem cell therapies, gene therapy if completed successfully would
likely require multiple procedures to re-introduce the desired vector. Additionally,
patients may experience unpredictable adverse effects several months after treatment,
which is currently unknown due to the early stages of clinical trial many gene therapies
are in.
Implications of Early Age Onset and Treatment
One of the difficulties of any treatment targeting Retinitis Pigmentosa is both the
young age of onset and rapid nature of photoreceptor loss. Photoreceptor loss due the
disease can begin to occur in young adults although age of onset varies widely, often
correlating to which gene is affected. With the discovery of more of the genes which
induce retinitis pigmentosa diseases, early diagnosis has become far more common.
However, once noticeable symptoms begin to be displayed many rod photoreceptors have
been lost due to the disease. As discussed earlier, no current treatments exist that have the
ability to rescue lost photoreceptors after apoptosis has occurred and only stem cell
therapy has been seen to rescue those that have entered dormancy. This issue was
exemplified in the gene therapy treatment of the PDE6A dogs as the injections worked
most effectively at approximately 36 days post birth and in only still developing eyes.
This creates difficulties for researchers as often young patients would benefit most from
and be ideal patients for treatments designed to stop photoreceptor death as they would be
in early stages of disease progression. However, experimental clinical testing is not often
conducted on children, as parents would be unlikely to allow their children who have not
yet experienced loss of vision to participate. This calls for a treatment which would be
safe for children. Antioxidant treatment stands out, as if an effective cocktail can be
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created children could take these supplements orally, removing the need for multiple
clinical visits, injections, or surgeries. Intravenous input of stem cells also appears to be a
more child friendly approach when compared to the subretinal injection of gene therapy,
or sub-tenon injection of stem cells, decreasing the need for doctor visits and invasive
procedures.
Convenience and Requirement of Recurring Visits
With treatments one must consider the convenience of treatment as well as the
requirement of physician administration and therefore doctors’ visits in order to
administer treatment. In the case of a discovered antioxidant treatment likely they could
be taken orally requiring only a prescription appointment and check-in intervals to
determine the effectiveness of treatment. This set-up is far different than that of both gene
therapy and stem cell therapy treatments, although the duration between each treatment
may vary, both will require repeated injection or infusion in order to maintain decrease of
photoreceptor loss or visual gains, this means routine doctors’ visits for the patient as
well as repeated potentially invasive treatments to see sustaining positive effects.
Patient Exclusions of Each Therapy
One of the most attractive features of antioxidant therapy is its ability to
potentially decrease the loss of photoreceptor cells in all retinitis pigmentosa patients.
This treatment targets patients with remaining vision as it strives to mediate a
consequence of rod photoreceptor loss, instead of the more complicated cause of loss. In
theory, most retinitis pigmentosa diseases do not target the cone cells, but their death is
caused by the extremely oxygen saturated environment created when rod cells die. If
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cones were able to be preserved through these treatments, patients would only lose
peripheral vision as opposed to complete vision loss. If a treatment is completed, every
patient suffering from early stage retinitis pigmentosa and oxidative damage may be able
to have the remaining vision produced by cone cells. Though, any patients with complete
blindness, or substantial loss of cone photoreceptors could not be helped through this
treatment.
Similarly, stem cell therapy strives to serve a large percentage of retinitis
pigmentosa patients, the treatments can be used for those suffering from multiple
different forms of RP resulting from several different gene mutations. This form of
treatment is slightly less inclusive than antioxidants. All treatment subjects were required
to have no previous history of treatment mediation due to complications that could be
produced from interacting with previous interventions. Additionally, yet again, patients
already suffering from complete blindness or dramatically reduced vision, are unlikely to
see benefits from these treatments due to their inability to restore dead photoreceptor
cells.
Conversely, gene therapy approaches are often highly targeted to singular genes
and mutations. The genetic nature of the disease makes it a crucial target for gene
therapy, however since the group of diseases is so diverse, these methods must be highly
targeted and will only serve small percentages of retinitis pigmentosa patients per each
targeted therapy. As previously discussed, human trials have begun on patients displaying
X-linked PRGR mutations. If the treatment described does get approved by the FDA then
it will only benefit those with this mutation which include only relatively young males,
who are all evaluated for good health before trial, which means this method will likely
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exclude many older patients with more progressive stages of retinitis pigmentosa due to
other health concerns.
Conclusion of Most Promising Therapy
With the lack of a treatment that is currently in use to help Retinitis Pigmentosa
patients slow the loss of photoreceptor cells or regain lost site, the success of any of these
treatments would be a substantial triumph for patients and researchers alike. However,
they are not all created equal and through critical evaluation, stem cell therapy with
MCS’s through intravenous infusion appears to be the most promising. This treatment
can not only service a wide range of patients with few adverse effects, but also will be
able to potentially halt the rapid decline of photoreceptor cells. It also appears to be the
closest to approval and minimally invasive. It is difficult to dismiss treatment with
antioxidants as it could produce similar effects and would likely rank better in all of the
categories previously listed. However, its development is behind the other treatments and
thus has a more uncertain future. Additionally, gene therapy would likely provide better
results and could even restore lost vision, but with its highly targeted nature, can only
improve the lives of small portions of the retinitis pigmentosa community per perfected
treatment. When comparing the two forms of MSC injection, sub-tenon injection of
Wharton’s Jelly derived MSC’s does produce longer lasting results of photoreceptor
death decrease but requires time consuming culture of materials and eye injection, which
could lead to increased complications and adverse side effects with continuous injections.
In additional clinical trials, if intravenous stem cell therapy continues to be proven
safe and effective, trials will likely expand to broader age ranges and patients with more
progressive retinitis pigmentosa. With greater information of long term treatment effects
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through testing, more funds dedicated to the culture and distribution of intravenous
umbilical cord MSC’s, and greater awareness of this form of treatment, I predict this
treatment modality could be quickly heading to clinical approval. This would allow a
majority of retinitis pigmentosa patients a method of treatment which may halt disease
effects and photoreceptor death until a cure for the disease is discovered.
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